Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2008

Kerr SM, Liechty B, Patel R, Harrop JS. Percutaneous vertebral compression fracture management with polyethylene mesh-contained morcelized allograft bone. Curr Rev Musculoskelet Med. 2008;1(2):84-7.

Emanuel P, Qin L, Harpaz N. Calcifying fibrous tumor of small intestine. Ann Diagn Pathol. 2008;12(2):138-41.

Building a prostate. Nat Med. 2008;14(12):1317.

Godar S, Ince TA, Bell GW, Feldser D, Donaher JL, Bergh J, et al. Growth-inhibitory and tumor- suppressive functions of p53 depend on its repression of CD44 expression. Cell. 2008;134(1):62-73.

Lerou PH, Yabuuchi A, Huo H, Takeuchi A, Shea J, Cimini T, et al. Human embryonic stem cell derivation from poor-quality embryos. Nat Biotechnol. 2008;26(2):212-4.

Shmelkov SV, Butler JM, Hooper AT, Hormigo A, Kushner J, Milde T, et al. CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. J Clin Invest. 2008;118(6):2111-20.

Di Bartolo DL, Cannon M, Liu Y-, Renne R, Chadburn A, Boshoff C, et al. KSHV LANA inhibits TGF-beta signaling through epigenetic silencing of the TGF-beta type II receptor. Blood. 2008;111(9):4731-40.

Mark T, Jayabalan D, Coleman M, Pearse RN, Y Wang L, Lent R, et al. Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma. Br J Haematol. 2008;143(5):654-60.

Menu E, Garcia J, Huang X, Di Liberto M, Toogood PL, Chen I, et al. A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model. Cancer Res. 2008;68(14):5519-23.

Schaeffer EM, Marchionni L, Huang Z, Simons B, Blackman A, Yu W, et al. Androgen-induced programs for prostate epithelial growth and invasion arise in embryogenesis and are reactivated in cancer. Oncogene. 2008;27(57):7180-91.